Archive for the ‘Starlix’ Category

FROM THE BEGINING…

Saturday, October 4th, 2008

Do you have diabetes? Are you struggling to live with diabetes? Are you looking for information online about diabetes? Are you unsure as to what types of foods you should now be eating to help keep a check on your glucose levels? If you have answered yes to any of these questions this article may well be of interest and benefit to you.

Diabetes is a disease in which the body does not produce or properly use insulin. Insulin is a hormone that is needed to convert sugar, starches and other food into energy needed for daily life. The cause of diabetes continues to be a mystery, although both genetics and environmental factors such as obesity and lack of exercise appear to play roles.

There are 20.8 million children and adults in the United States, or 7% of the population, who have diabetes. While an estimated 14.6 million have been diagnosed with diabetes, unfortunately, 6.2 million people (or nearly one-third) are unaware that they have the disease.

In order to determine whether or not a patient has pre-diabetes or diabetes, health care providers conduct a Fasting Plasma Glucose Test (FPG) or an Oral Glucose Tolerance Test (OGTT). Either test can be used to diagnose pre-diabetes or diabetes.

With the FPG test, a fasting blood glucose level between 100 and 125 mg/dl signals pre-diabetes. A person with a fasting blood glucose level of 126 mg/dl or higher has diabetes.

In the OGTT test, a person’s blood glucose level is measured after a fast and two hours after drinking a glucose-rich beverage. If the two-hour blood glucose level is between 140 and 199 mg/dl, the person tested has pre-diabetes. If the two-hour blood glucose level is at 200 mg/dl or higher, the person tested has diabetes.

Major Types of Diabetes

Type 1 diabetes
Results from the body’s failure to produce insulin, the hormone that “unlocks” the cells of the body, allowing glucose to enter and fuel them. It is estimated that 5-10% of Americans who are diagnosed with diabetes have type 1 diabetes.

Type 2 diabetes
Results from insulin resistance (a condition in which the body fails to properly use insulin), combined with relative insulin deficiency. Most Americans who are diagnosed with diabetes have type 2 diabetes.

Medications for Type 2 Diabetes

Sulfonylureas:
- GLUCOTROL XL (Glipizide)
- AMARYL (Glimepiride)

Meglitinides:
- PRANDIN (Repaglinide)
- STARLIX (Nateglinide)

Biguanides:
- GLUCOPHAGE (Metformin)

Thiazolidinediones:
- ACTOS (Pioglitazone)
- ACTOPLUS MET (Pioglitazone/Metformin)
- AVANDIA (Rosiglitazone)
- AVANDAMET (Rosiglitazone/Metformin)

Other medications:
- KARELA and DIABECON

Gestational diabetes
Gestational diabetes affects about 4% of all pregnant women – about 135,000 cases in the United States each year.

Pre-diabetes
Pre-diabetes is a condition that occurs when a person’s blood glucose levels are higher than normal but not high enough for a diagnosis of type 2 diabetes. There are 54 million Americans who have pre-diabetes, in addition to the 20.8 million with diabetes.

Additional Information

Recently Diagnosed
You or someone you love has just been diagnosed with diabetes — chances are you have a million questions running through your head. This area of our Web site can help ease your fears and teach you more about living with diabetes or caring for someone with diabetes, and connect you with others affected by diabetes who will listen and share their own experiences.

Diabetes Symptoms
Often diabetes goes undiagnosed because many of its symptoms seem so harmless. Learn what they are in this section.

Diabetes Risk Test
More than 20 million Americans have diabetes — nearly one in three does not know it! Take our diabetes risk test to see if you are at risk for having diabetes. Diabetes is more common in African Americans, Latinos, Native Americans, Asian Americans and Pacific Islanders.

Diabetes Myths
Find the truth about some of the most common myths about diabetes.

The Genetics of Diabetes
You’ve probably wondered how you got diabetes. You may worry that your children will get it too. Unlike some traits, diabetes does not seem to be inherited in a simple pattern. Yet clearly, some people are born more likely to get diabetes than others.

  • Share/Bookmark

STARLIX (Nateglinide)

Thursday, December 20th, 2007

Meglitinides

Meglitinides are drugs that also stimulate the beta cells to release insulin. Repaglinide (brand name Prandin) and nateglinide (Starlix) are meglitinides. They are taken before each of three meals.

Product Description

Most important information about Starlix

Pharmacokinetics

Possible Side Effects

More information about STARLIX (Nateglinide) :

Starlix Combination Therapy

Starlix approved for use in combination with thiazolidinedione class of antidiabetic drugs

Study: Starlix enhances glucose control in people with impaired tolerance

To get more information about Starlix: STARLIX MEDICATION.

To buy STARLIX (Nateglinide) click HERE: My Family Drugstore

  • Share/Bookmark

STARLIX (Nateglinide) Study: Starlix enhances glucose control in people with impaired tolerance

Tuesday, December 18th, 2007

New research presented at the World Congress of Cardiology describes results from the first study to show that Starlix (nateglinide) enhances early insulin secretion and controls post-prandial blood glucose in people with impaired glucose tolerance (IGT). This suggests that Starlix may be a useful agent for controlling post-prandial hyperglycaemia in this pre-diabetic patient group.

It is estimated that as many as 150 million people may have IGT. People with IGT show abnormalities in both insulin secretion and response to insulin (insulin sensitivity), and are at high risk of progressing to type 2 diabetes, with a 40-50% chance of developing the disease within ten years. IGT is an intermediate state between normal blood glucose control and type 2 diabetes and is characterised by an excessive rise in blood glucose following an oral glucose tolerance test. IGT is also a major risk factor for cardiovascular disease.

Dr Leif Groop of the University of Lund in Sweden, one of the study’s lead investigators, commented: “Loss of early insulin secretion is one of the first pathophysiological signs of progression to type 2 diabetes. By restoring the normal, physiological pattern of insulin secretion, nateglinide essentially normalised glucose tolerance in these patients”.

The study, which took place at centers in six European countries, involved 288 people with IGT. Results showed that Starlix enhanced early insulin secretion and reduced both the size of the blood glucose peak and the total increase in blood glucose over the three hours following the meal. Fasting glucose levels were not affected.

People with IGT are the ideal population to be involved in diabetes prevention trials. The mode of action of nateglinide and its excellent safety profile have led to its inclusion in the NAVIGATOR trial launched in November 2001. NAVIGATOR will be the largest diabetes prevention trial to date, involving 7,500 subjects in 40 countries, and will determine whether long-term administration of Starlix (60 mg before main meals) or the angiotensin II receptor blocker Diovan (valsartan) (160 mg a day) prevents or delays type 2 diabetes and cardiovascular disease in people who have IGT and are at high cardiovascular risk.

Dr Richard Pratley, Medical Director for the NAVIGATOR trial at Novartis Pharma Corp explained: “With type 2 diabetes increasing rapidly all over the world, it is now vital that we explore prevention strategies. This study demonstrates the clear rationale for including Starlix in the NAVIGATOR trial. NAVIGATOR will show us whether restoring early insulin secretion with Starlix can slow decline to type 2 diabetes and prevent cardiovascular disease in this high-risk group.”

Product Description

Most important information about Starlix

Pharmacokinetics

Possible Side Effects

More information about STARLIX (Nateglinide) :

Starlix Combination Therapy

Starlix approved for use in combination with thiazolidinedione class of antidiabetic drugs

To buy STARLIX (Nateglinide) click HERE: My Family Drugstore

  • Share/Bookmark

STARLIX (Nateglinide) Starlix approved for use in combination with thiazolidinedione class of antidiabetic drugs

Monday, December 17th, 2007

EAST HANOVER, N.J., October 23, 2003 — Novartis announced that the FDA had approved Starlix (nateglinide) for use in combination with a thiazolidinedione (TZD) in patients with type 2 diabetes who are not adequately controlled after a therapeutic response to a TZD.

TZDs are a commonly used class of oral antidiabetic agents in the treatment of type 2 diabetes. Starlix was approved in the U.S. in 2001 as monotherapy for drug-naive patients with type 2 diabetes and in combination with metformin, a leading oral antidiabetic agent. With this new indication of adding Starlix to a TZD, physicians now have a new option for controlling and maintaining blood sugar levels of patients with type 2 diabetes.

Research has shown that improved glycemic control, as measured by a reduction of HbA(1c) levels, may lead to a dramatic lowering of deaths and complications from diabetes. Even a 1 percent reduction in HbA(1c) can correlate to a 21 percent decrease in deaths from diabetes and a 14 percent decrease in heart attacks. Additional research shows that over time there is a progressive need for multiple therapies in order to effectively treat type 2 diabetes and maintain a target HbA(1c) of less than 7.0 percent.

FDA approval of this new indication is based on the findings of a 24-week, multi-center, double-blind, randomized study which compared the efficacy of Starlix (120 mg, taken before a meal) and placebo added to rosiglitazone (Avandia(R) 8 mg, q.d.) in 402 patients with type 2 diabetes who had not reached target HbA(1c) levels on rosiglitazone alone.

The study found that the addition of Starlix reduced HbA(1c) from 8.3 percent to 7.5 percent while HbA(1c) remained unchanged for patients on rosiglitazone and placebo. The overall safety, tolerability and effects on lipid parameters for the combination were similar to rosiglitazone alone. Weight gain associated with Starlix use in this study was 2 kg compared to placebo. Peripheral edema was no more common in patients using the combination of Starlix and rosiglitazone than in patients receiving rosiglitazone alone.

Source: NovartisPharmaceuticals Corporation www.pharma.novartis.com or www.novartis.com

Product Description

Most important information about Starlix

Pharmacokinetics

Possible Side Effects

More information about STARLIX (Nateglinide) :

Starlix Combination Therapy

Study: Starlix enhances glucose control in people with impaired tolerance

To buy STARLIX (Nateglinide) click HERE: My Family Drugstore

  • Share/Bookmark

STARLIX (Nateglinide) Starlix Combination Therapy

Saturday, December 15th, 2007

Starlix Combination Therapy: Metformin
In another randomized, double-blind, 24-week, active- and placebo-controlled study, patients with Type 2 diabetes were randomized to receive Starlix (120 mg three times daily before meals), metformin 500 mg (three times daily), a combination of Starlix 120 mg (three times daily before meals) and metformin 500 mg (three times daily), or placebo. Baseline HbA1C ranged from 8.3% to 8.4%. Fifty-seven percent of patients were previously untreated with oral antidiabetic therapy. Patients previously treated with antidiabetic medications were required to discontinue medication for at least 2 months before randomization. The combination of Starlix and metformin resulted in statistically significantly greater reductions in HbA1C and FPG compared to either Starlix or metformin monotherapy. Starlix, alone or in combination with metformin, significantly reduced the prandial glucose elevation from pre-meal to 2-hours post-meal compared to placebo and metformin alone.
In this study, one episode of severe hypoglycemia (plasma glucose ? 36 mg/dL) was reported in a patient receiving the combination of Starlix and metformin and four episodes of severe hypoglycemia were reported in a single patient in the metformin treatment arm. No patient experienced an episode of hypoglycemia that required third party assistance. Compared to placebo, Starlix monotherapy was associated with a statistically significant increase in weight, while no significant change in weight was observed with combined Starlix and metformin therapy.
In another 24-week, double-blind, placebo-controlled trial, patients with Type 2 diabetes with HbA1C? 6.8% after treatment with metformin (? 1500 mg daily for ? 1 month) were first entered into a four week run-in period of metformin monotherapy (2000 mg daily) and then randomized to receive Starlix (60 mg or 120 mg three times daily before meals) or placebo in addition to metformin. Combination therapy with Starlix and metformin was associated with statistically significantly greater reductions in HbA1C compared to metformin monotherapy (-0.4% and -0.6% for Starlix 60 mg and Starlix 120 mg plus metformin, respectively).

Starlix Combination Therapy: Rosiglitazone
A 24-week, double blind multicenter, placebo-controlled trial was performed in patients with Type 2 diabetes not adequately controlled after a therapeutic response to rosiglitazone monotherapy 8 mg daily. The addition of Starlix (120 mg three times per day with meals) was associated with statistically significantly greater reductions in HbA1C compared to rosiglitazone monotherapy. The difference was -0.77% at 24 weeks. The mean change in weight from baseline was about +3 kg for patients treated with Starlix plus rosiglitazone vs about +1 kg for patients treated with placebo plus rosiglitazone.

Starlix Combination Therapy: Glyburide
In a 12-week study of patients with Type 2 diabetes inadequately controlled on glyburide 10 mg once daily, the addition of Starlix (60 mg or 120 mg three times daily before meals) did not produce any additional benefit.

Product Description

Most important information about Starlix

Pharmacokinetics

Possible Side Effects

More information about STARLIX (Nateglinide) :

Starlix approved for use in combination with thiazolidinedione class of antidiabetic drugs

Study: Starlix enhances glucose control in people with impaired tolerance

To buy STARLIX (Nateglinide) click HERE: My Family Drugstore

  • Share/Bookmark